Antagonizing activity of vaccinia virus E3L against human interferons in Huh7 cells  by Arsenio, Janilyn et al.
Virology 377 (2008) 124–132
Contents lists available at ScienceDirect
Virology
j ourna l homepage: www.e lsev ie r.com/ locate /yv i roAntagonizing activity of vaccinia virus E3L against human interferons in Huh7 cells
Janilyn Arsenio b, Yvon Deschambault a, Jingxin Cao a,b,⁎
a Division of Viral Diseases, Bloodborne Pathogens and Hepatitis, National Microbiology Laboratory, Public Health Agency of Canada, Winnipeg, Manitoba Canada R3E 3R2
b Department of Medical Microbiology and Infectious Diseases, University of Manitoba, Winnipeg, Manitoba Canada R3E 0W3⁎ Corresponding author. Division of Viral Diseases
Hepatitis, National Microbiology Laboratory, Public Healt
Manitoba Canada R3E 3R2. Fax: +1 204 789 2082.
E-mail address: jingxin_cao@phac-aspc.gc.ca (J. Cao)
0042-6822/$ – see front matter. Crown Copyright © 20
doi:10.1016/j.virol.2008.04.014.A B S T R A C TA R T I C L E I N F OArticle history: The E3L protein of vaccini
Received 20 February 2008
Accepted 8 April 2008
Available online 27 May 2008
Keywords:
Vaccinia virus
E3L
IFN
PKR
Huh7a virus (VV) is well known for its capacity to evade cellular innate antiviral
immunity related to interferon (IFN), for example PKR and RNaseL mediated antiviral activities. However, due
to the limited range of cells that support VV E3L deletion mutant replication, the full capacity of E3L
inhibiting the innate immune response induced by IFNs remains to be examined. In this report, the inhibition
activity of VV E3L against a wide spectrum of human IFNs, including type I IFNs (12 IFN-α subtypes, IFN-β,
and IFN-ω), and type II IFN (γ), was comparatively examined using the Copenhagen strain E3L deletion
mutant and its revertant control virus in a human hepatoma cell line, Huh7. Deletion of the E3L open reading
frame rendered the mutant VV sensitive to all types of IFNs, while the revertant VV was strongly resistant to
these treatments. Furthermore, we show that the inhibition of VV E3L deletion mutant by IFN occurs at the
stage of intermediate gene translation, while the expression of early genes and transcription of intermediate
genes are largely unaffected. Using speciﬁc siRNAs to suppress the classical IFN-induced antiviral pathways,
we found that PKR is the key factor modulated by E3L, while the RNaseL and MxA pathways play limited
roles in this Huh7 cell system. Thus, our data demonstrates that VV E3L can mediate strong inhibition activity
against all human type I and type II IFNs, mainly through modulation of the PKR pathway in Huh7 cells.
Crown Copyright © 2008 Published by Elsevier Inc. All rights reserved.IntroductionInterferons (IFNs) play a pivotal role in innate immunity against viral
infections. Inmammals, IFNs thatmediate antiviral activity include: type I
IFNs, composed of several IFN-α subtypes, IFN-β, and IFN-ω and a single
member of type II IFNs, IFN-γ. Themore recent described IFNs-λ1,λ2, and
λ3 (alternatively knownas IL-29, IL-28A/B), are induced by viral infections
similar to type I IFNs, and have been shown to exhibit antiviral and
antiproliferative activities in vitro and in response to poxvirus infection in
vivo (Meager et al., 2005; Onoguchi et al., 2007; Bartlett et al., 2005). Both
type I and type II IFNs induce the JAK/STAT signaling pathway in all
nucleated cell types and transcriptionally regulate several interferon
stimulated genes (ISGs) that result in the production of antiviral proteins,
including PKR, 2′–5′ OAS, and myxovirus resistance protein (MxA). All
IFN-α subtypes are similar in structure and share a common receptor
(IFNAR1/2), and can elicit antiviral activity, but may also vary in their
ability to activate signaling pathways in certain cell types, and are likely to
induce different genes (Foster and Finter,1998; Pestka et al., 2004; Pfeffer,
1997; Yano et al., 2006). Thus, it is entirely possible that different IFN
subtypes may initiate different degrees of antiviral activity., Bloodborne Pathogens and
h Agency of Canada,Winnipeg,
.
08 Published by Elsevier Inc. All rigMillions of years of virus and host co-evolution have led viruses to
develop a wide variety of strategies to antagonize IFN activity. Of
interest, a dsRNA binding protein encoded by vaccinia virus (VV), E3L,
is well known for its capacity to block IFN induction, signaling, and
activity. IFN inducible dsRNA-dependent Protein Kinase R (PKR) and
2′–5′-oligoadenylate synthetase (2′–5′ OAS) are activated in the
presence of dsRNA which leads to the inhibition of translation
initiation through eIF2α phosphorylation and the degradation of
mRNA by ribonuclease RNaseL, respectively (Garcia et al., 2006;
Carroll et al., 1997). Competitive binding of E3L to dsRNA inhibits the
activation and overall function of both PKR and 2′–5′ OAS and has
been associated with the inhibition of IRF-3 phosphorylation and the
suppression of IFN-β induction (Chang et al., 1992; Davies et al., 1993;
Xiang et al., 2002; Smith et al., 2001). The similar strategy to
antagonize IFN antiviral function through dsRNA binding is also
used by several other vertebrate viruses such as reovirus σ3, HSV-1
US11, avian reovirus σA, and inﬂuenza virus NS1 (Imani and Jacobs,
1988; Jacobs and Langland,1998; Langland et al., 2006; Lu et al., 1995).
Deletion of E3L (VVΔE3L) is associated with a highly restricted host
range. For example, in comparisonwith thewild-type virus, VVΔE3L is
unable to replicate in Vero, murine L929, or HeLa cells (Beattie et al.,
1996; Langland and Jacobs, 2002; Shors et al., 1998, 1997). It is well
known that PKR and RNaseL, both of which can be regulated by IFNs,
play major roles in determining the highly restricted host range of a
VV E3L deletion mutant (Langland and Jacobs, 2002; Beattie et al.,
1996; Xiang et al., 2002). However, the interplay between E3L and IFN-
induced cellular responses (which involves more than 300 genes) inhts reserved.
125J. Arsenio et al. / Virology 377 (2008) 124–132relation to virus replication has not beenwell characterized due to the
limited cell lines available for such analysis. Previous studies on IFN
sensitivity of a VV E3L deletion mutant were based on HeLa (Langland
and Jacobs, 2004) or L929 cells (Beattie et al., 1995a,b; Xiang et al.,
2002). However, in these cells, the replication of a VV E3L deletion
mutant is defective. A VV E3L deletion mutant can replicate in rabbit
kidney, RK-13 cells (Chang et al., 1995), and was shown to be sensitive
to treatment with rabbit IFN-α in this cell line (Shors et al., 1997).
Nonetheless, it is unlikely that the true capacity of E3L inhibiting
human IFN antiviral activity can be analyzed using these cell lines and
the interplay between E3L and IFN-induced antiviral signaling
remains unclear.
In this study, we found that the VV E3L deletion mutant can
efﬁciently replicate in Huh7 cells. Using this cell line, we show that E3L
can mediate potent inhibition on antiviral activity induced by type I
and type II IFNs through modulation of the PKR pathway.
Results
The VV E3L deletion mutant can replicate efﬁciently in the human
hepatoma cell line Huh7
The E3L deletion mutant (Cop-ΔE3L) and its revertant (Cop-ΔE3L-
Rev) were constructed based on the Copenhagen strain as described in
Materials and methods. The only difference between the E3L deletion
mutant and revertant viruses is the absence and presence of the E3L
ORF, respectively (Fig. 1a). We conﬁrmed the absence and presence of
the E3L protein in the E3L deletion mutant and revertant viruses byFig. 1. Conﬁrmation of the deletion of VV E3L in the E3L deletion mutant and the
expression of E3L in the revertant control viruses. (a) Total RNA was extracted from
BHK21 cells infected with Cop-ΔE3L, Cop-ΔE3L-Rev, and wild-type VV Cop. RT-PCR
analysis conﬁrm E3LmRNA expression is absent in the BHK21 cell control (lane 1), and
in the E3L deletion mutant (Cop-ΔE3L) (lane 3), but is present inwild-type VV Cop (lane
2) and in the revertant control (Cop-ΔE3L-Rev) (lane 4). Deletion of E3L did not affect
the mRNA expression of adjacent ORFs, E2L and E4L. (b) Human hepatocellular
carcinoma, Huh7 cells, efﬁciently support Cop-ΔE3L replication. Conﬂuent cell
monolayers were infected at a MOI of 1 with wild-type VV Copenhagen strain (Cop)
and Cop-ΔE3L and harvested 5 and 24 hpi. Virus titres (log10 pfu/ml) were measured in
triplicate. Error bars indicate standard error of the mean.Western blot (data not shown). The difference between the revertant
virus and the wild-type Copenhagen strain is the inclusion of gpt (for
positive selection) and EGFP for easy plaque identiﬁcation and
orientation of the E3L ORF. The inclusion of gpt and EGFP has no
effect on virus replication and IFN sensitivity (data not shown). As
shown in Fig. 1a, the mRNA expression of two adjacent ORFs, E2L and
E4L, was not affected by deletion of E3L. The replication capability of
the E3L deletion mutant was tested in six human cell lines and
compared to BHK21. The human hepatoma cell line Huh7, was the
only cell line to efﬁciently support replication of the E3L deletion
mutant, while the E3L deletion mutant completely failed to replicate
in MRC5, AD293, and HeLa cells (Fig. 1b).
VV E3L is a potent inhibitor to all human type I and type II interferons in
Huh7 cells
Huh7 cells have been reported to be responsive to human type I
IFNs (Blight et al., 2002). We conﬁrmed the Huh7 cell line we used in
this study is responsive to both type I and type II IFNs by activation of
STAT1 by phosphorylation at two residues, tyrosine 701 and serine
727 (Supplementary Fig. 1).
To analyze the inhibition activity of the E3L protein on human IFNs
in Huh7 cells, Cop-ΔE3L and its revertant were comparatively
analyzed for their sensitivity to both type I and type II IFNs (including
the 12 IFN-α subtypes, IFN-β, IFN-ω, and IFN-γ) (Fig. 2). As shown in
Fig. 2a, Cop-ΔE3L-Rev is resistant to treatment of all type I and type II
IFNs tested, depicted by the consistent pattern of replication of the
revertant virus in the presence of all IFN species. Generally, a slight
decrease in Cop-ΔE3L-Rev replication is seen with an IFN dose of 200
to 2000U/ml of type I and type II IFN species.
In contrast, deletion of the E3L gene results in a dramatic increased
sensitivity to all human IFN species: IFN-β, IFN-ω, IFN-γ, and the IFN-
α subtypes. As illustrated in Fig. 2b, replication of Cop-ΔE3L is
inhibited in the presence of type I and type II IFNs in a dose-dependent
manner. Even at a low dose of 20U/ml, IFN species demonstrated
potent inhibition, decreasing virus replication by 100-fold, seen in IFN-
β, IFN-ω, and IFN-γ treated Huh7 cells. Among all IFNs tested, the
most potent IFN species was IFN-α14, which inhibited replication of
Cop-ΔE3L by 1000-fold at its highest dose of 2000U/ml. Following
IFN-α14, were type I IFNs: IFN-α2a, IFN-β, and type II IFN-γ, each of
which inhibited replication of Cop-ΔE3L between 100 to 1000-fold. In
contrast, the least effective at inhibiting viral replication was IFN-α7,
followed by IFN-α5.
Cop-ΔE3L IFN sensitivity is mediated by PKR
To further characterize the mechanism of IFN resistance of Cop-
ΔE3L-Rev and sensitivity of Cop-ΔE3L mutant viruses (Fig. 2), we
examined the roles of each of the three main IFN-induced classical
antiviral pathways: PKR, 2′–5′ OAS/RNaseL, and MxA pathways.
Since IFNs transcriptionally induce PKR, to investigate the PKR
pathway, we ﬁrst monitored any change in endogenous PKR protein
levels in type I (leukocyte, -β,-ω) and type II (γ) IFN-treated Huh7
cells in the absence and presence of virus infection with Cop-ΔE3L-
Rev and Cop-ΔE3L. As shown in Fig. 3a, the level of PKR in Cop-
ΔE3L-Rev infected Huh7 cells is comparable to the level of PKR in the
cell control in the absence of IFN treatment. However, the level of
total PKR appears to be reduced in Huh7 cells infected with Cop-
ΔE3L in the absence of IFN treatment. Treatment with type I
(leukocyte, -β,-ω) and type II (γ) IFNs slightly enhanced the level of
endogenous PKR in the absence of virus infection. Even in the pres-
ence of both type I and type II IFNs, total PKR seems to be slightly
reduced in all Cop-ΔE3L infected cells, whereas in all Cop-ΔE3L-Rev
infected cells, there is no difference in PKR in the absence or
presence of IFN treatment. It is important to note that the antibody
used in this study recognizes endogeneous PKR protein and was
Fig. 2. Comparative analysis of the sensitivity of Cop-ΔE3L-Rev and Cop-ΔE3L to type I and type II human IFNs. (a) Replication of Cop-ΔE3L-Rev is resistant to IFN treatment.
(b) Replication of Cop-ΔE3L is inhibited by type I and type II human IFNs in a dose-dependent manner. Huh7 cell monolayers (5×105 cells/ml) were pretreated with human IFNs (12
IFN-α subtypes, IFN-β, ω, and γ) at different concentrations of 0, 2, 20, 200, or 2000 U/ml for 24 h at 37 °C. The IFN-treated cells were infected at a MOI of 1, with Cop-ΔE3L-Rev or
Cop-ΔE3L and harvested 24 h later. Titrations were performed in triplicate. Error bars indicate standard error of the mean.
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residue, Thr451. Thus, because of this antibody's speciﬁcity at
detecting endogeneous PKR, the absolute total PKR protein level
may not be fully detected as PKR dimerizes and autophosphorylates
following virus infection. We next examined the activation/phos-
phorylation of PKR and corresponding phosphorylation changes in
its substrate, eIF2α. Fig. 3a demonstrates phosphorylated PKR is in
abundance following infection with Cop-ΔE3L and is enhanced after
IFN treatment. A minimal level of phosphorylated PKR is present in
Huh7 cells infected with Cop-ΔE3L-Rev in the absence and presence
of IFN treatment. Total eIF2α levels slightly increased post viral
infection, regardless of IFN treatment. The level of phosphorylated
eIF2α increases after viral infection and IFN treatment. The only
exception is observed in IFN-β treated Huh7 cells, in which total
eIF2α and phosphorylated eIF2α is slightly reduced in the absence of
virus infection (Fig. 3a). Although infection with both Cop-ΔE3L-Rev
and Cop-ΔE3L induced eIF2α phosphorylation, a signiﬁcantly greater
level of phosphorylated eIF2α is present in Huh7 cells infected with
Cop-ΔE3L than Cop-ΔE3L-Rev.
To further characterize the role of the PKR pathway in the IFN
sensitivity of Cop-ΔE3L, we used siRNA to speciﬁcally suppress the
expression of PKR inHuh7 cells. Huh7 cells transfectedwith PKR siRNA
were treated with 100U/ml of leukocyte IFN, IFN-β, IFN-ω, and IFN-γ
and infected with Cop-ΔE3L for 24h. In all cells transfected with PKR
siRNA (Fig. 3b), the expression of PKR was signiﬁcantly reduced. Sup-
pression of PKR in Huh7 cells abolished the effect of type I and type II
IFN antiviral activity, in that when transfected with PKR siRNA, the
replication of Cop-ΔE3L in the presence of type I and type II IFNswas at
the same level as or higher than the control without IFNs (Fig. 3c). In
addition, in comparison with the control cells not transfected or
transfectedwith the negative siRNA, the knockdown of PKRexpressionsigniﬁcantly enhanced the replication of Cop-ΔE3L in Huh7 cells not
treated with IFN.
It is intriguing that transfection with the negative siRNA also
moderately enhanced Cop-ΔE3L replication. To verify that transfection
of Huh7 cells with this negative siRNA does not affect the antiviral
activity of type I and type II IFNs, Huh7 cells were also transfected with
the negative control siRNA then subsequently treatedwith 100U/ml of
leukocyte IFN, IFN-β, IFN-ω, and IFN-γ and infected with Cop-ΔE3L.
The E3L deletionmutant remains sensitive to IFN treatment, indicating
that the increase in virus titre in all negative control siRNA transfected
cells in the absence of IFN treatment is an effect speciﬁc to this par-
ticular control siRNA, regardless of Cop-ΔE3L IFN sensitivity to type I
and type II IFN (Fig. 3c).
RNaseL is not expressed in the Huh7 cells
To examine the role of the 2′–5′ OAS/RNaseL pathway in the
cellular response to Cop-ΔE3L infection, wemonitored RNaseL activity
by measuring 28S and 18S rRNA degradation in IFN-treated and VV
infected Huh7 cells. As depicted in Fig. 4a, RNaseL activity was not
detected in Huh7 cells observed at 6 and 12hpi. Given the limited
RNaseL activity in this cell system, we monitored the endogeneous
RNaseL protein in Huh7 cells and in a positive control, HeLa-S3 cells,
by Western blot. Total RNaseL protein was undetectable in Huh7 cells
even in the presence IFN treatment and virus infection, yet present in
HeLa-S3 cells (Fig. 4b). To further examine the endogenous expression
of RNaseL mRNA, we performed RT-PCR analysis of RNA extracted
from Huh7 cells treated with type I and type II IFNs and infected with
both Cop-ΔE3L and Cop-ΔE3L-Rev. As shown in Fig. 4c, RNaseLmRNA
is detected in HeLa-S3 cells, while it is not detected in Huh7 cells even
in the presence of IFN treatment and virus infection. Since we were
Fig. 3. E3L evades the PKR/eIF2α pathway in Huh7 cells. (a)Western blot analysis of endogenous and phosphorylated levels of PKR and eIF2α in Huh7 cells with no IFN (lanes 1, 2, and
3) or treated with leukocyte IFN (lanes 4, 5, and 6), IFN-β (lanes 7, 8, and 9), IFN-ω (lanes 10, 11, and 12), IFN-γ (lanes 13, 14, and 15), and infected with Cop-ΔE3L-Rev (R) or Cop-ΔE3L
(Δ). (b) Western blot conﬁrms the knockdown of PKR protein levels in Huh7 cells transfected with PKR siRNA in the absence (lane 3) and presence of leukocyte IFN (lane 5), IFN-β
(lane 7), IFN-ω (lane 9), and IFN-γ (lane 11). Controls include Huh7 cells only (lane 1), and negative siRNA transfection (lane 2). (c) Knockdown of the PKR pathway by siRNA enhances
Cop-ΔE3L replication in the absence and presence of type I and type II IFNs in Huh7 cells. Negative siRNA transfections do not affect Cop-ΔE3L IFN sensitivity. Huh7 cells were
untreated (control) and transfected with negative siRNA (negative), PKR siRNA, and treated with leukocyte IFN, IFN-β, IFN-ω, and IFN-γ. PKR and negative siRNA transfected cells and
IFN treatment are as indicated. Titrations were performed in triplicate. Error bars indicate standard error of the mean.
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blot and RT-PCR, RNaseL does not contribute to the IFN sensitivity of
Cop-ΔE3L in Huh7 cells.
IFN-induced MxA does not inhibit Cop-ΔE3L replication
Although the antiviral mechanism of MxA remains unknown, IFN-
induced MxA expression has been linked to the inhibition of virus
gene transcription, viral mRNA translation, and virus nucleocapsids
transportation of several RNA viruses (Hefti et al., 1999). Currently, no
evidence has been reported of the role of MxA in the cellular immune
response to poxviruses. To examine the inhibitory potential of MxA
activity with regards to Cop-ΔE3L replication, we used MxA speciﬁc
siRNA to knockdown the expression of MxA and observed this effect
on virus replication. The knockdown of MxA expression in Huh7 cells
transfected with MxA siRNA and treated with leukocyte IFN, IFN-β,
IFN-ω, and IFN-γ was conﬁrmed by RT-PCR (Fig. 5a). Type I IFNs
(leukocyte IFN, IFN-β, and IFN-ω) induced stronger MxA expression
than IFN-γ. MxA expressionwas not detected in cells not treated with
IFN. Knockdown of MxA in Huh7 by siRNA did not signiﬁcantly affect
the ability of the E3L deletion mutant to replicate in the absence or
presence of leukocyte IFN, IFN-β, IFN-ω, or IFN-γ (Fig. 5b). Cop-ΔE3Lremained sensitive to type I and type II IFN treatment in Huh7 cells
transfected with MxA siRNA.
IFNs inhibit translation of intermediate genes in Cop-ΔE3L infections
As we have observed a stronger level of eIF2α phosphorylation in
Cop-ΔE3L than in Cop-ΔE3L-Rev infected Huh7 cells (Fig. 3a), we next
investigated the association of such eIF2α phosphorylation with virus
protein synthesis. We measured the effect of IFN treatment on the
expression of two VV genes, an early gene, D12L, which encodes for a
capping enzyme (Higman et al., 1994), and an intermediate gene, G8R,
whose protein product has been identiﬁed as a late transcription
factor (Keck et al., 1990). RT-PCR analysis demonstrate the mRNA
expression of D12L and G8R in Huh7 cells infected with both the
revertant control and E3L deletionmutant viruses was not impaired in
either the absence or presence of type I and type II IFNs (Fig. 6a).
However, at the level of protein expression, translation of the early
gene, D12L, was largely unaffected in either the absence or presence of
IFN or virus infection. In contrast, type I IFN treatment completely
blocked translation of G8R, while type II IFN treatment also signif-
icantly inhibited G8R protein synthesis. It should be noted that G8R
protein translation was compromised in Cop-ΔE3L infections in
Fig. 4. (a) No RNaseL activity is present in Huh7 cells treated with type I and II IFNs and
infected with Cop-ΔE3L-Rev (R) and Cop-ΔE3L (Δ). 18S and 28S ribosomal subunits
remain intact 6 and 12 hpi as indicated. (b) RNaseL protein is detected in HeLa-S3 cells
(lane 1) and is absent in Huh7 cells in the absence of IFN treatment and virus infection
(lane 2) and in the presence of leukocyte IFN (lanes 5, 6, and 7), IFN-β (lanes 8, 9, 10),
IFN-ω (lanes 11, 12, 13), and IFN-γ (lanes 14, 15, and 16) and virus infection with Cop-
ΔE3L-Rev (R) and Cop-ΔE3L (Δ). (c) RNaseLmRNA expression is present in HeLa-S3 cells
(lane 1), but is undetectable in Huh7 cells untreated or treated with type I and type II
IFNs and infected with Cop-ΔE3L-Rev (R) and Cop-ΔE3L (Δ) as indicated.
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treatment (Fig. 6b). This partial block of G8R may account for the
difference in the replication capacity between Cop-ΔE3L and Cop-
ΔE3L-Rev in Huh7 cells (Fig. 1b).
Discussion
IFNs can regulate the expression of over 300 genes (de Veer et al.,
2001). PKR and RNaseL pathways are the two best characterized
innate antiviral immune responses regulated by IFNs. It is well known
that vaccinia E3L, a double-stranded RNA binding protein, plays a
critical role in determining the virus tropism by inhibiting activation
of PKR and RNaseL (Langland and Jacobs, 2004; Beattie et al., 1996;
Xiang et al., 2002). IFN-induced antiviral activities, including activa-
tion of PKR and RNaseL, against vaccinia virus were examined in HeLa
(Langland and Jacobs, 2004) or L929 (Beattie et al., 1995b) cells using a
wild-type vaccinia virus and its E3L deletion mutant. However, the
replication of the E3L deletion mutant virus is defective in these cell
lines even without IFN treatment. By co-expression of E3L, IFN-
induced antiviral activities can be compromised against VSV replica-
tion (Shors et al., 1998). A rabbit kidney cell line, RK13, can efﬁciently
support Cop-ΔE3L replication and this replication could be blocked by
rabbit IFN-α (Chang et al., 1995). However, due to the limitedavailability of reagents, E3L mediated IFN resistance particularly
against human IFNs was not comprehensively examined. In this
report, we describe a human hepatoma cell line Huh7, which is IFN
responsive and can efﬁciently support the replication of a vaccinia E3L
deletionmutant. The capacity of vaccinia E3L suppressing both human
type I (12 IFN-α subtypes, IFN-β, and IFN-ω) and type II (IFN-γ) IFN-
induced antiviral activities against vaccinia virus was investigated
using this cell line. In this study, we demonstrated that VV E3L plays
the major role in mediating antagonistic activity against all human
type I and type II IFNs in a human liver carcinoma cell line, Huh7. To
our knowledge, we provide the ﬁrst comprehensive analysis of the
inhibitory activity of E3L against all human type I and type II IFNs in a
human cell line. In this report, we made three contributions to
characterizing the IFN antagonizing properties of VV E3L. First, we
identify a human cell line, Huh7 cells, which can efﬁciently support
the replication of the VV E3L deletionmutant and is suitable to further
examine the antiviral activity of a wide range of human IFNs and/or
viral IFN antagonists. Second, in this Huh7 cell system,we conclusively
demonstrated that VV E3L is a universal antagonist against both type I
and type II IFNs. Third, in this speciﬁc virus/cell system, PKR is the
major IFN regulated signal suppressed by VV E3L.
In humans, several type I IFN species: 12 IFN-α subtypes, IFN-β, IFN-
ω, and one type II IFN-γ have been identiﬁed. Interferon-regulatory
factor 3 (IRF-3),mediates theﬁrstwave of IFN-α4 and IFN-β production,
and is followed by the expression of the latent transcription factor,
interferon regulatory factor 7 (IRF-7), which mediates the second wave
of IFNproduction, inducing expression of IFN-α2,α5,α6, andα8 (Pestka
et al., 2004; Levy et al., 2003; Sato et al., 2000; Decker et al., 2002). The
difference in induction times and variable biological functions asso-
ciated with the 12 IFN-α subtypes make it possible for variable degrees
of antiviral strength. We show that different IFN-α subtypes exhibit
different levels of inhibition activity against the E3L deletion mutant.
The speciﬁc mechanisms underlying this variation in inhibition activity
among IFN-α subtypes and type II IFN remain to be investigated.
The E3L deletion mutant induced a greater degree of eIF2α
phosphorylation than infection with the revertant virus in both the
absence and presence of IFN treatment (Fig. 3a). The increased level of
eIF2α phosphorylation associated with Cop-ΔE3L infectionmay play a
critical role in IFN-induced inhibition of the virus replication, since it
has been shown that a 10–20% difference of eIF2α phosphorylation
could have signiﬁcant impact on the inhibition of protein translation
(Hinnebusch, 2000).
In Cop-ΔE3L-Rev infected Huh7 cells, phosphorylated eIF2α was
present although a low level of phosphorylated PKR was detected
(Fig. 3a). In addition to PKR, three other cellularkinases havebeen shown
to phosphorylate eIF2α in regulating global translation in response to
distinct stimuli. These kinases include GCN2, triggered by amino acid
starvation; PERK, activated by cellular stress and protein misfolding at
the ER membrane; and HRI, which is responsive to iron deﬁciency (He,
2006). It is possible that theseadditional kinasesmaycontribute to eIF2α
phosphorylation in Cop-ΔE3L-Rev infected cells, although the actual
kinase involved in this case is unknown. In the system described in this
study, the level of phosphorylatedPKRcoincideswith theenhanced level
of eIF2α phosphorylation in Cop-ΔE3L infected Huh7 cells (Fig. 3a). This
is in agreementwith several previous studies, which have shown that an
increased level of eIF2α phosphorylation induced by Cop-ΔE3L infection
is associated with an increased level of PKR/phosphorylated PKR (Chang
et al., 1992; Sharp et al., 1998; Seet et al., 2003). In the present study, we
are the ﬁrst to show this association in the context of IFN treatment and
virus infection. In addition, we clearly show that speciﬁc suppression of
PKR level by siRNA in Huh7 cells rescues Cop-ΔE3L replication upon
type I and type II IFN treatment. Apart from its dsRNA binding capability
and the subsequent inhibition of PKR activation, the E3L protein has also
been shown to directly bind to both regulatory and substrate binding
regions of PKR and inhibit PKR function (Sharp et al., 1998). Thus, our
data indicates that the E3Lprotein exerts its antagonizingactivity against
Fig. 5. Effect of MxA knockdown by siRNA on the replication of Cop-ΔE3L in Huh7 cells in the absence and presence of type I and type II IFNs. (a) Knockdown of type I and type II IFN-
induced MxA expression in Huh7 cells by siRNA, conﬁrmed by RT-PCR. (b) Effect of MxA activity on Cop-ΔE3L replication. Huh7 cells transfected with MxA siRNA and treated with
type I and type II IFNs are as indicated. Virus control in Huh7 cells only (control) and negative siRNA transfection control (negative siRNA) are included. Titrations were performed in
triplicate. Error bars indicate standard error of the mean.
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phosphorylation, in the cell system described here. In addition to its
classical role in phosphorylating eIF2α, PKR is also implicated in the
regulation of other signaling pathways such as proinﬂammatory
cytokines, growth factors, oxidative stress and apoptosis (Garcia et al.,
2006) and such activities may also contribute to the IFN-induced in-
hibition of Cop-ΔE3L replication in Huh7 cells described in this report
and pathogenesis in vivo.Fig. 6. IFN treatment inhibits VV intermediate protein synthesis. (a) Transcription of VV
early gene, D12L, and intermediate gene, G8R, is not affected by IFN treatment in Huh7
cells infected with Cop-ΔE3L-Rev (R) or Cop-ΔE3L (Δ). Total RNA was extracted from
Huh7 cells treated with 1000 U/ml of leukocyte IFN, IFN-β, IFN-ω, and IFN-γ for 24 h at
37 °C and infected with Cop-ΔE3L-Rev (R) and Cop-ΔE3L (Δ) at a MOI of 5 for 6 h. D12L,
G8R and human GAPDH as a control were ampliﬁed by RT-PCR. (b) Absence of the G8R
protein in all Cop-ΔE3L mutant infected Huh7 cells treated with type I and type II IFNs.
Western blot analysis of Huh7 cells treated with type I and type II IFNs (1000 U/ml) and
infected with Cop-ΔE3L-Rev (R) and Cop-ΔE3L (Δ) at a MOI of 5 for 6 h, using polyclonal
antibodies against D12L and G8R.A recent study has shown that PKR is the key factor in determining
the replication defective phenotype of the VV E3L deletion mutant in
HeLa cells (Zhanget al., 2008). It requires at least 12h of incubation (data
not shown) for IFNs to mount effective antiviral signaling, while
replication of the VV E3L deletion mutant is aborted at early times of
infection (Ludwig et al., 2006; Chang et al.,1992). Therefore, it is unlikely
that PKR mediated antiviral activity, which is antagonized by the E3L
protein, in HeLa cells is regulated by IFN. Here, we present strong
evidence showing that the E3L protein antagonizes antiviral signaling
pathways inducedby IFN, inwhichPKR is themainplayer. Since IFNs can
regulate the expression level of greater than 300 genes simultaneously
(de Veer et al., 2001), it is very likely that themechanismof IFN-induced
and PKRmediated antiviral signaling observed in Huh7 cells is different
to the recent report on the role of PKR in restricting the replication of the
vaccinia E3L deletion mutant in HeLa cells (Zhang et al., 2008).
Evasion of the 2′–5′ OAS pathway by E3L was shown in various cell
systems that include PKR knockout murine ﬁbroblasts and immorta-
lizedMEFswhose constitutive RNaseL expression suppressed VVΔE3L,
but had no effect on wild-type VV (Rivas et al., 1998; Xiang et al.,
2002). More recently, the E3L protein of modiﬁed vaccinia virus (MVA)
was shown to inhibit the 2′–5′ OAS/RNaseL pathway in HeLa cells
(Ludwig et al., 2005). Although the 2′–5′ OAS/RNAseL pathway is
induced by both type I and type II IFNs, the induction of antiviral
pathways may be cell type-speciﬁc (Stark et al., 1998). In this study,
RNaseL activity was not detectable in Huh7 cells treated with type I
and type II IFNs during VV infection. We further demonstrate the lack
of RNaseL mRNA and protein expression in this cell line. Therefore, the
role of E3L inhibiting RNaseL mediated antiviral activity cannot be
evaluated using Huh7 cells as described in this report.
However, it is plausible to further investigate the role of E3L at
inhibiting RNaseL activity using this human cell line. To elucidate the
function of RNaseL in inhibiting replication of the E3L deletionmutant,
we can generate constitutively expressing Huh7-RNaseL cell lines.
This would allow for an expanded characterization of VV E3L and its
inhibition of RNaseL activity in human cells.
MxA is induced primarily by type I IFNs or type III IFNs (Haller et al.,
2007) and has been reported to inhibit both RNA and DNA viruses
(Stark et al., 1998; Gordien et al., 2001; Bartlett et al., 2005). The
130 J. Arsenio et al. / Virology 377 (2008) 124–132mechanism by whichMxA inhibits viral replication remains unknown
and the role of this IFN-induced protein in suppressing vaccinia virus
replication has not been elucidated. In this study, we found that MxA
has limited activity in suppressing Cop-ΔE3L replication. Knockdown
of MxA gene expression by siRNA does not signiﬁcantly abolish the
antiviral activity of either type I or type II IFNs against Cop-ΔE3L. It is
also possible that MxA mediated antiviral signaling is defective in
Huh7 cells, as this antiviral activity has been shown to be cell type-
speciﬁc (Schneider-Schaulies et al., 1994; Landis et al., 1998).
VV replication was shown to be sensitive to pretreatment with
murine IFNs-α/β in Balb/c mice and that this inhibition is associated
with the blockageof early viral gene expression (Rodriguez et al.,1991).
In the human cell line, Huh7, we show that both type I and type II IFNs
inhibit intermediate ORFs translation of a VVmutant devoid of the E3L
ORF, while early and intermediate gene transcription is unaffected.
IFNs exert a different spectrum of antiviral activity through synchro-
nizing with other cellular factors such as TNF-α in vivo in comparison
with the in vitro tissue culture system (Zuniga et al., 2007). Since G8R is
a late gene transcriptional activator, it is predictable that late gene
expression is blocked. Moreover, in the presence of IFN treatment, in
the E3L deletion mutant infections, the G8R protein is absent. Apart
from antagonizing PKR induced eIF2α phosphorylation, it is also
possible that E3L can directly regulate the expression of other VV genes
involved in viral transcription and/or translation. In fact, a recent study
that describes the association of VV transcription and translationwith
cytoplasmicDNA factories illustrates the relocation of E3L to theseDNA
factories at times post-infection at which intermediate and late viral
gene expression would occur (Katsafanas and Moss, 2007).
In this report, we demonstrate that VV E3L is a potent inhibitor of
both type I and type II human IFNs. We found that the main
mechanism bywhich VV E3L inhibits human IFN activity in Huh7 cells
is by modulation of the PKR pathway. Of importance, VV E3L and its
homologs in other human pathogenic orthopoxviruses are highly
conserved. Thus, the IFN antagonizing activity of VV E3L described in
this report is signiﬁcant to the understanding of human orthopoxvirus
immunopathogenesis. Collectively, this report highlights an excellent
human cell line system in which to study the inhibition activity of a
strong IFN antagonist, VV E3L, against all human type I and type II IFN
species. This system has the potential in studying other viral IFN
antagonistic proteins whose means of innate evasion is primarily by
modulation of the PKR pathway.
Materials and methods
Cell culture and viruses
Baby hamster Kidney (BHK21), HeLa-S3, HepG2, SW13, MRC5,
AD293 (ATCC) and Human Hepatoma (Huh7) (provided by Dr. G.Y.
Minuk, University of Manitoba) cell lines were maintained in
Dulbecco's Modiﬁed Eagle's Medium (DMEM) supplemented with
10% fetal bovine serum and antibiotics (Invitrogen). The virus used in
this study is vaccinia virus Copenhagen strain (provided by Dr. G.
McFadden, University of Florida).
Human interferons
Type I IFNs (12 IFN-α subtypes, IFN-β1a, IFN-ω), leukocyte IFN (a
mixture of IFN-α subtypes and IFN-ω) and type II IFN (IFN-γ) were
purchased from PBL Biomedical Laboratories.
Construction of VV Copenhagen E3L deletion (pΔE3L/EGFP) and E3L
deletion-Revertant (pΔE3L/EGFP-Rev) recombinant vectors
For homologous recombination, the left and right ﬂanking regions
of the E3L gene were PCR ampliﬁed using VV Copenhagen strain
genomic DNA as the template. The left ﬂanking regionwas synthesizedwith primer pair of E3L_FLF (ATTACTCGAGTGATGTTCATATATTGGTT-
TTGTCCCGGGTTGAAGCTTACTACATATGAGAATGCTAGCTAGATTCT-
GATTCTAGTTATCAATAACA), while the right ﬂanking region was
synthesized with primer pair of E3L_FRF (ATCTAGCTAGCATTCTCA-
ACAACCAGCAATAAAACTGAACCTACT) and E3L_FRR (TGGCGAGCTCT-
CTAA). The complementary sequences representing multiple cloning
sites are shown in bold and italics. The left and rightﬂanking sequences
were ligated bya second round PCRwith primers FLFand FRR andwere
inserted into cloning vector pBS-KS+ (Stratagene) between the XhoI
and SacI sites, resulting in plasmid pΔE3L. Sequence ﬁdelity was
conﬁrmed. The gpt gene driven byan early and late promoter, p7.5, was
subcloned into pΔE3L at the SmaI site. A cassette containing EGFP gene,
driven by an early and late promoter, was cloned between NheI and
NdeI sites, yielding VV Copenhagen E3L deletion vector.
To construct the revertant control vector, the E3L gene and its
authentic promoter region was PCR ampliﬁed from VV Copenhagen
strain genomic DNA with primer pairs E3L_N-XhoI 5′-ATTACTCGA-
GATTTCGCAATCTTAATGTTACAACG-3′ and E3L_C-SmaI 5′-ATAACCC-
GGGTCAGAATCTAATGATGACGTAACCAA-3′. The E3L gene was cloned
into pΔE3L/EGFP, resulting in plasmid pΔE3L-Rev.
Generation of VV Copenhagen E3L deletion and control ΔE3L-Revertant
recombinant viruses
5 μg of plasmid DNA pΔE3L/EGFP (for generation of the E3L deletion
mutant, Cop-ΔE3L) was transfected into BHK21 cells infected with
Copenhagen strain wild-type using Effectene Transfection Reagents
according to the manufacturer's instructions (Qiagen). Recombinant
poxvirus was grown in selective media containing mycophenolic acid
(Falkner and Moss, 1988), and puriﬁed after 4 rounds of plaque
puriﬁcation. For generation of the revertant control virus, 5 μg of
plasmid DNA pΔE3L-Rev was transfected into BHK21 cells infectedwith
the E3L deletion mutant virus. The purity of the Cop-ΔE3L mutant and
revertant control Cop-ΔE3L-Rev viruses was conﬁrmed by PCR with
primer pair ﬂanking the E3LORF, forward primer 5′-TGATAAAGTAGGTT-
CAGTTTTATTGCTGGTTGT-3′ and reverse primer 5′-TGTTATTGATAACTA-
GAATCAGAATCTA-3′. Adjacent ORFs were ampliﬁed by PCR with the
following primer pairs: E2L forward primer 5′-TGGATTCTGTCCAATGAT-
GATGAAACG -3′ and reverse primer 5′-TCTTCCCTCTATCATGTTCAC-
TACTGG-3′; E4L forward primer 5′-ATACATTAGTAGTTACTCATCCAA-3′
and reverse primer 5′-ATCATCCTCTGGTGGTTCGTCGTT-3′.
Interferon sensitivity assays
Huh7 cell monolayers were grown in 12-well culture plates to 80%
conﬂuency and subsequently treated overnight at 37 °C with varying
concentrations of human IFNs (12 Human IFN-α subtypes, IFNs-β, ω,
and γ) at 0, 2, 20, 200, or 2000 U/ml. Cell monolayers were infected at
amultiplicity of infection (MOI) of 1 with either Cop-ΔE3L-Rev or Cop-
ΔE3L recombinant viruses and incubated at 37 °C. One hour post-
infection (hpi), total virus and media containing IFN were aspirated,
and replaced with fresh media containing the same concentration of
IFN, and incubated for an additional 24 h at 37 °C. Control wells
contained growth media without IFN.
Plaque assays
Cop-ΔE3L-Rev and Cop-ΔE3L viruses were collected 24 hpi and
serial dilutions of each were used to infect 100% conﬂuent BHK21 cell
monolayers. To calculate virus titre (pfu/ml), plaques were enumer-
ated 24 hpi under UV. Titrations were performed in triplicate.
Western blot
Western blots were performed to examine the proﬁle of signaling
proteins in Huh7 cells primed with type I and type II IFNs. In brief,
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leukocyte IFN, IFNs-β, ω, and γ, and infected at a MOI of 5 with either
Cop-ΔE3L-Rev or Cop-ΔE3L. To inhibit cellular phosphatase activity,
Phosphatase Inhibitor Cocktail I (Sigma-Aldrich) was added to all
wells 6 hpi, prior to cell lysis in PBS containing SDS. Proteins were
separated by electrophoresis on 4–12% polyacrylamide gels (Bio-Rad)
in 1× XT Mops Running Buffer (Bio-Rad) at 150 V for 1 h, transferred
onto H-bond nitrocellulose membranes (Amersham Biosciences) at
150 mA for 1 h, and the membranes were incubated with polyclonal
antibodies against STAT1 (Upstate) and phospho-STAT1 (Y701)
(Upstate), phospho-STAT1 (S727) (Cell Signaling Technology), PKR
and phospho-PKR (T446) (Epitomics), and eIF2α and phospho-eIF2α
(S51) (Biosource) in 5% skimmilk in TBST (1× Tris–borate sulphate and
0.2% Tween 20). Polyclonal antibodies for VV D12L and VV G8R were
prepared against the peptide sequences RERDAIKSNNHLTE and
TPGNTDAFSREYSM, respectively (Genscript). A monoclonal antibody
against human RNaseL (Cell Signaling Technology) was also used in
this study. Proteins were detected using chemiluminescence-based
Western Lightning Reagents (PerkinElmer LAS, Inc).
RNA gel for RNaseL activity
Huh7 cells were treated with 1000 U/ml of leukocyte IFN, IFN-β,
IFN-ω, and IFN-γ, and infected at a MOI of 5 with either Cop-ΔE3L-Rev
or Cop-ΔE3L. Total RNA was extracted 6 and 12 hpi using the RNeasy
Mini Kit (Qiagen) according to the manufacturer's protocol. Samples
were prepared according to the NorthernMax Protocol (Ambion, Inc.)
and loaded onto 1% agarose-LE (Ambion, Inc.), electrophoresed at
100 V for 1 h, and visualized under UV light.
PKR and MxA RNA silencing
Huh7 cells were seeded at 3×105 cells per well in 6-well culture
plates and transfected with 100 nM of small interfering RNA (siRNA)
speciﬁc to human PKR 5′-P-ACUUUGUCUAGUUUCUCGCUU, and MxA
5′-P-UUCGUCUUCCGGUAUGUCGUU (Dharmacon RNA Technologies)
and Silencer Cy3-Labeled Negative Control #1 (Catalog #4621, Ambion,
Inc.) using Hiperfect Transfection Reagent (Qiagen) in DMEM and
incubated at 37 °C. 48 h later, cells were treated with 100 U/ml of
leukocyte IFN, IFN-β, IFN-ω, and IFN-γ overnight, then infected at a
MOI of 1 with Cop-ΔE3L. Virus titres were determined by plaque
assays. PKR silencing was conﬁrmed byWestern blot with an antibody
against PKR (Cell Signaling Technology), and the suppression of MxA
was conﬁrmed by RT-PCR.
Reverse transcription polymerase chain reaction (RT-PCR)
Reverse transcription was performed using Advantage RT-for-PCR
Kit (Clontech) according to the manufacturer's instructions. Negative
cDNA controls were prepared under identical reaction conditions
without reverse transcriptase. PCR was performed with MxA for-
ward primer 5′-AAGGTCAGTTACCAGGACTACGAGA-3′ and reverse
primer 5′-ACAATCATGTAACCCTTCTTCAGGT-3′; human RNaseL for-
ward primer 5′-TATGGCTTCACAGCCTTCATGGAA-3′ and reverse pri-
mer 5′-ACAATCTGTACTGGCTCCACGTTT-3′; human GAPDH forward
primer 5′-AAGGTGAAGGTCGGAGTCAACGGA-3′ and reverse primer 5′-
TTACTCCTTGGAGGCCATGT-3′;vvD12L forwardprimer 5′-ATGGATGAAAT-
TGTAAAAAATATCCGGGA-3′ and reverse primer 5′-TCACAGCAGTAGTTTA-
ACTAGTCT-3′; vvG8R forward primer 5′-AATGTAGACTCGACGGATGAGTTA-
3′ and reverse primer 5′-TCGTCATTATCCATTACGATTCTAGTT-3′.
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